Lloyd Mitchell Segal - 04 Mar 2025 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)

Role: PRESIDENT AND CEO, Director
Signature: /s/ Steve Forte, Attorney-in-Fact
Issuer symbol: RPTX
Transactions as of: 04 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 06 Mar 2025, 17:00:12 UTC
Previous filing: 01 Apr 2024
Next filing: 14 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RPTX	Common Shares	Award	$0	+40,000	+38%	$0.000000	145,573	04 Mar 2025	Direct	F1, F2
holding	RPTX	Common Shares						107,558	04 Mar 2025	See footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RPTX	Employee Stock Option (right to buy)	Award	$0	+237,000		$0.000000	237,000	04 Mar 2025	Common Shares	237,000	$1.17	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. Thirty-three and one third percent (33 1/3%) of the RSUs shall vest on each of March 4, 2026, March 4, 2027 and March 4, 2028, subject to Reporting Person continuing to provide service through each such date.
F2	Includes 895 and 2,000 shares acquired on August 15, 2024 and February 15, 2025, respectively, under the Issuer's employee stock purchase plan.
F3	These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company.
F4	Twenty-five percent (25%) of the shares subject to the option shall vest on March 4, 2026, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.